Biopharmaceutical company BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for agitation treatment Igalmi.  Igalmi (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I and II in adults.   In April 2022, Igalmi was approved by the FDA as the first and only orally […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!